Modeling of Blood–Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research
International Journal of Molecular Sciences · 12.06.2024 · 25 (12) · 6496
DOI: 10.3390/ijms25126496 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.06.2024. Verfasst von Masato Ohbuchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Cell Movement, Lab-On-A-Chip Devices, Endothelial Cells. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma (Japan), Astellas Pharma Inc..
Abstract (Originalsprache)
Blood–brain barrier (BBB) dysfunction is a key feature in neuroimmunological and neurodegenerative diseases. In this study, we developed a microfluidic human BBB-on-a-chip to model barrier dysfunction and immune cell migration using immortalized TY10 brain endothelial cells, pericytes, and astrocytes. It was found that immortalized TY10 brain endothelial cells developed a microvascular structure under flow. Pericytes were localized on the basal side surrounding the TY10 microvascular structure, showing an in vivo-like structure. Barrier integrity increased under co-culture with pericytes. In addition, both ethylenediaminetetraacetic acid (EDTA) and anti-Claudin-5 (CLDN5) neutralizing antibody caused a decrease in the transendothelial electrical resistance (TEER). EDTA caused the leakage of 20 kDa dextran, suggesting different effects on the BBB based on the mechanism of action, whereas anti-CLDN5 antibody did not cause leakage. In the tri-culture model, human T cells migrated through endothelial vessels towards basal C-X-C motif chemokine ligand 12 (CXCL12). The live-imaging analysis confirmed the extravasation of fluorescence-labelled T cells in a CXCL12-concentration- and time-dependent manner. Our BBB model had an in vivo-like structure and successfully represented barrier dysfunction and transendothelial T cell migration. In addition, our study suggests that the inhibition of CLDN5 attenuates the BBB in humans. This platform has various potential uses in relation to the BBB in both drug discovery research and in elucidating the mechanisms of central nervous system diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied Research & Operations, Astellas Pharma Inc., Tsukuba 305-8585, Ibaraki, Japan.
- Department of Neurology and Clinical Neuroscience, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, Yamaguchi, Japan.
ORCID-Profile: Masayo Oishi, Fumitaka Shimizu
Förderung
- Astellas Pharma (Japan)
- Astellas Pharma Inc.
Zitieren
APA
Ohbuchi, M., Shibuta, M., Tetsuka, K., Sasaki-Iwaoka, H., Oishi, M., Shimizu, F., & Nagasaka, Y. (2024). Modeling of Blood–Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research. International Journal of Molecular Sciences, 25(12), 6496. https://doi.org/10.3390/ijms25126496
Vancouver
Ohbuchi M, Shibuta M, Tetsuka K, Sasaki-Iwaoka H, Oishi M, Shimizu F, et al. Modeling of Blood–Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research. International Journal of Molecular Sciences. 2024;25(12):6496. doi:10.3390/ijms25126496
BibTeX
@article{Ohbuchi2024,
author = {Ohbuchi, Masato and Shibuta, Mayu and Tetsuka, Kazuhiro and Sasaki-Iwaoka, Haruna and Oishi, Masayo and Shimizu, Fumitaka and Nagasaka, Yasuhisa},
title = {Modeling of Blood–Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6496},
doi = {10.3390/ijms25126496}
}
EUVIMED